# Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

> **NCT07246564** · PHASE4 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 40 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** Rozanolixizumab

## Key facts

- **NCT ID:** NCT07246564
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-10-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246564, "Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07246564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*